Login to Your Account



Endovasc Ending Research Into NRA For Liprostin Focus

By Karen Pihl-Carey


Friday, May 27, 2005
Placing more resources toward and greater attention on its product Liprostin for peripheral arterial occlusive disease, Endovasc Inc. decided to stop funding preclinical research of a nicotine receptor agonist (NRA) in coronary artery disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription